Abstract: Disclosed herein are compositions comprising recombinant arenavirus monoclonal antibodies and antigen-binding fragments thereof, as well as therapeutic methods using the antibodies. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains.

Abstract: Described herein are antiviral peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for treating or inhibiting a viral infection or one or more symptoms of a viral infection.

Abstract: Disclosed herein are compositions comprising arenavirus monoclonal antibodies, as well as therapeutic, diagnostic, and preventative methods using the novel antibodies. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules, peptides) that inhibit Old World arenavirus infectivity, including LASV and LCMV. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains. Diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses are also disclosed, as well as new tools and methods for the design, production, and use of arenavirus monoclonal antibodies, including expression in engineered bacterial- and mammalian-based systems.

Abstract: Disclosed herein are compositions comprising arenavirus monoclonal antibodies, as well as therapeutic, diagnostic, and preventative methods using the novel antibodies. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules, peptides) that inhibit Old World arenavirus infectivity, including LASV and LCMV. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains. Diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses are also disclosed, as well as new tools and methods for the design, production, and use of arenavirus monoclonal antibodies, including expression in engineered bacterial- and mammalian-based systems.

Abstract: Disclosed herein are compositions comprising arenavirus monoclonal antibodies, as well as therapeutic, diagnostic, and preventative methods using the novel antibodies. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules, peptides) that inhibit Old World arenavirus infectivity, including LASV and LCMV. In some embodiments, the antibodies provide pan-arenavirus protection against a number of arenavirus types and strains. Diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses are also disclosed, as well as new tools and methods for the design, production, and use of arenavirus monoclonal antibodies, including expression in engineered bacterial- and mammalian-based systems.

Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.

Abstract: The present invention provides compositions and methods for treating a measles virus infection. A pharmaceutical composition comprises a polypeptide in a biocompatible pharmaceutical carrier, in which the polypeptide consists of at least a portion of SEQ ID NO: 5 or SEQ ID NO: 6. A method embodiment comprises administering the polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a measles infection.

Abstract: The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.

Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.

Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.

Abstract: The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.

Abstract: The present invention provides compositions and methods for treating a measles virus infection. A pharmaceutical composition comprises a polypeptide in a biocompatible pharmaceutical carrier, in which the polypeptide consists of at least a portion of SEQ ID NO: 5 or SEQ ID NO: 6. A method embodiment comprises administering the polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a measles infection.

Abstract: The present invention provides compositions and methods for treating a coronavirus infection. A method embodiment comprises administering a polypeptide (preferably in a biocompatible pharmaceutical carrier) to a subject suffering from a coronavirus infection. The polypeptide comprises or consists of at least a portion of the fusion initiation region (FIR) of a coronavirus fusion protein. In some embodiments, the polypeptide comprises or consists of a sequence selected from SEQ ID NO: 2, 22, 23, 24, and 25 or an 8 to 40 contiguous amino acid residue portion thereof.

Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.

Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).

Abstract: Soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g. small molecules) that inhibit LASV infectivity, and diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.

Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).

Abstract: The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.

Abstract: The present invention provides peptides, peptide analogs, peptide derivatives and pharmaceutical compositions useful for treating or preventing influenza infections or preventing the person-to-person transmission of an influenza infection. A peptide of the invention comprises an influenza virus-cell fusion inhibiting portion of the fusion initiation region (FIR) of a wild-type influenza hemagglutinin 2 protein or a variant thereof. In a preferred embodiment, a peptide of the invention consists of 8 to 40 consecutive amino acid residues a portion of a wild-type influenza hemagglutinin 2 protein or a variant thereof, the portion of the protein comprising the FIR of the protein and up to five amino acid residues on the amino-terminal and carboxy-terminal sides of the FIR.

Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.